{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-272814","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.625562+00:00","generated_at":"2026-05-29T05:44:19.343014+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcellx iMMagine-1 study: 97% ORR, 62% CR/sCR, no delayed neurotoxicity in RRMM","bullets":["Phase 2 pivotal iMMagine-1: 86 patients evaluable; ORR 97% (83/86), CR/sCR 62% (53/86) at median 9.5-month follow-up.","No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) in >150 dosed patients across Phase 1 and iMMagine-1.","Phase 1 study shows 30.2-month median PFS at 38.1 months follow-up; median OS not reached.","MRD negativity achieved in 93.1% (54/58) evaluable at ≥10⁻⁵ sensitivity.","Safety: 86% had Grade ≤1 CRS; 91% had no ICANS; most common Grade ≥3 TEAE was neutropenia (54%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-272814","json":"https://secwatch.observer/filing/0001193125-24-272814.json","markdown":"https://secwatch.observer/filing/0001193125-24-272814.md","text":"https://secwatch.observer/filing/0001193125-24-272814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524272814/0001193125-24-272814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524272814/d917635d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:44:19.343014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}